Inovio Pharmaceuticals, Inc.
2.4300-0.15 (-5.81%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · INO · USD
Key Stats
Market Cap
129.14MP/E (TTM)
-Basic EPS (TTM)
-2.59Dividend Yield
0%Recent Filings
8-K
Inovio cuts losses, advances BLA
Inovio Pharmaceuticals reported Q2 2025 net loss of $23.5 million, down from $32.2 million last year, as R&D expenses dropped to $14.5 million from $23.1 million amid focused spending on INO-3107. The company completed device testing and requested rolling BLA submission for INO-3107 in 2H25, targeting FDA acceptance by year-end and potential 2026 launch for RRP treatment. Cash stood at $47.5 million, bolstered by $22.5 million from a July stock offering, funding operations into Q2 2026. Long-term data showed sustained surgery reductions for RRP patients.
10-Q
Q2 FY2025 results
Inovio Pharmaceuticals narrowed its Q2 net loss to $23.5M from $32.2M y/y, with operating expenses dropping 31% to $23.1M on lower R&D for INO-3107 and other programs, while revenue stayed flat at nil. YTD net loss improved to $43.2M from $62.7M, driven by 30% lower operating costs and a $1.8M gain from warrant liability fair value changes, though EPS widened to $(1.12) from $(2.48) on higher shares outstanding (38.7M vs 25.2M). Cash burn eased to $47.7M YTD from $57.0M, leaving $47.5M in cash and equivalents at quarter-end, bolstered by $22.5M from a July offering extending runway into Q2 2026. No free cash flow disclosed in the 10-Q. Litigation with GeneOne settled in August, clearing a key overhang. Yet competition in DNA medicines intensifies.
8-K
Inovio prices $25M offering
Inovio Pharmaceuticals inked an underwriting deal on July 2, 2025, to sell 14,285,715 shares of common stock plus Series A and B warrants at $1.75 each, targeting $25 million in gross proceeds. Net proceeds should hit $22.5 million after fees, with closing eyed for July 7, assuming no hiccups. Series A warrants expire in 12 months or 30 days post-FDA BLA acceptance for INO-3107; Series B last five years. Yet market volatility could derail the close.
8-K
Annual meeting results approved
Inovio Pharmaceuticals held its 2025 Annual Meeting on May 20, with 54.59% of shares present. All eight director nominees won election, Ernst & Young LLP's auditor role was ratified overwhelmingly, and the 2023 Omnibus Incentive Plan amendment passed despite opposition. Executive pay drew mixed support. Shareholders endorsed governance continuity amid biotech pressures.
10-Q
Q1 FY2025 results
Inovio narrowed its Q1 net loss to $19.7M from $30.5M a year earlier, thanks to a 23% drop in operating expenses to $25.1M, driven by lower R&D costs for INO-3107 and reduced stock-based compensation, while revenue ticked up to $65K from collaborative arrangements. The operating loss improved to $25.1M from $31.5M y/y, with diluted EPS at -$0.51 versus -$1.31, confirmed against 38.6M weighted shares; no anti-dilution flagged. Cash and equivalents fell to $39.9M from $65.8M q/q, with $68.4M total liquidity supporting operations into Q1 2026, bolstered by $1.1M from at-the-market sales, though no debt or FCF disclosed. Ongoing litigation with VGXI and GeneOne poses a key risk, potentially draining resources amid tight funding.
ENTA
Enanta Pharmaceuticals, Inc.
10.63+0.16
GOVX
GeoVax Labs, Inc.
0.55-0.05
INAB
IN8bio, Inc.
2.00-0.10
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
INVA
Innoviva, Inc.
17.57-0.12
MRNA
Moderna, Inc.
24.70-0.65
NNVC
NanoViricides, Inc.
1.86+0.33
NVAX
Novavax, Inc.
8.38-0.14
REGN
Regeneron Pharmaceuticals, Inc.
652.91-1.57
VIR
Vir Biotechnology, Inc.
5.91-0.52